Insulet traded at $222.72 this Friday July 1st, increasing $4.78 or 2.19 percent since the previous trading session. Looking back, over the last four weeks, Insulet gained 4.13 percent. Over the last 12 months, its price fell by 20.84 percent. Looking ahead, we forecast Insulet to be priced at 221.60 by the end of this quarter and at 204.20 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
222.72
Daily Change
2.19%
Yearly
-20.84%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Abiomed 248.21 0.70 0.28% -21.71%
Abbott 108.33 -0.32 -0.29% -8.23%
Align Technology 241.03 4.36 1.84% -61.38%
AtriCure 40.70 -0.16 -0.39% -49.77%
Avanos Medical Inc 27.25 -0.09 -0.33% -25.81%
Baxter International 64.25 0.02 0.03% -21.42%
Becton, Dickinson and Co. 247.83 1.30 0.53% -0.25%
Boston Scientific 37.25 -0.03 -0.07% -15.20%
Cardinal Health 52.36 0.09 0.17% -9.54%
Cooper Companies 315.13 2.01 0.64% -22.71%
Cardiovascular Systems 14.51 0.15 1.04% -65.99%
Dexcom 75.91 1.38 1.85% -82.41%
Edwards Lifesciences 95.28 0.19 0.20% -10.61%
Globus Medical 56.23 0.09 0.16% -28.61%
Integra LifeSciences 54.17 0.14 0.26% -22.50%
ICU Medical 165.60 1.21 0.74% -20.33%
Inogen 24.07 -0.11 -0.45% -62.47%
J&J 177.01 -0.42 -0.24% 4.75%
Eli Lilly 319.27 -4.96 -1.53% 36.46%
Masimo 133.77 3.10 2.37% -46.92%
Medtronic 89.61 -0.14 -0.16% -29.35%
Merit Medical Systems 54.92 0.65 1.20% -14.21%
NuVasive 48.68 -0.48 -0.98% -27.77%
Insulet 222.72 4.78 2.19% -20.84%
Roche Holding 320.40 1.85 0.58% -8.34%
Sientra 0.82 -0.02 -2.46% -89.76%
Stryker 198.26 -0.67 -0.34% -25.30%
Teleflex 251.97 6.12 2.49% -38.54%
Tandem Diabetes Care 59.78 0.59 0.99% -39.38%
West Pharmaceutical Services 302.11 -0.26 -0.09% -17.40%
Zimmer Biomet Holdings Inc 104.95 -0.11 -0.10% -35.82%

Indexes Price Day Year
USND 10989 -39.60 -0.36% -24.93%
US2000 1702 -5.51 -0.32% -26.16%

Insulet
Insulet Corporation is primarily engaged in the development, manufacture and sale of its proprietary Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. It can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.